AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
For 70% of migraine patients, the new orally disintegrating zolmitriptan (Zomig) tablet is preferable to the conventional tablet, Dr. Andrew J. Dowson reported at WONCA 2001, the conference of the World Organization of Family Doctors.
He reported on a randomized, multi-center trial involving 471 migraine patients. Participants received either a placebo tablet or a 2.5-mg tablet of zolmitriptan in the new formulation that dissolves rapidly on the tongue to treat a single, moderate to severe episode of acute migraine.
In the patient-preference portion of the study, 78% of those in the zolmitriptan group said that they found the new formulation more convenient than the conventional tablet, with which they were familiar from ...
Source: HighBeam Research, Patients Like New Zolmitriptan.